Obtaining a deeper mechanistic understanding of the signaling mechanisms by which DCs control T cell responses, such as the BTLA-HVEM-CD5 axis described here, is necessary for the development of new immunotherapies for the treatment of cancer, autoimmunity, and infection. The gene discussed is BTLA; the disease is cancer.